Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial

Proteinuria Clinical Trial

Official title:

an Open Parallel Clinical Trial in HBV-GN Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01152060
• Other study ID #: NCT00100504
• Status: Active, not recruiting
• Phase: N/A
• First received: June 28, 2010
• Last updated: June 28, 2010
• Start date: January 2010
• Est. completion date: November 2010

Study information

• Verified date: May 2010
• Source: Nanchang University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Lamivudine treatment for HBV-DNA negative HBV-GN patients.

Description:

lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 10
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative

Exclusion Criteria:

• Primary MN patients, HBV-DNA positive

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• HBVe-antigen
• Proteinuria

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Nanchang University